Q4 2022 Aadi Bioscience Inc Earnings Call
Speaker 1: Good day and thank you for standing by. Welcome to the Addi Bioscience fourth quarter 2022 earnings call.
Speaker 1: At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session.
Speaker 1: To ask a question during the session, you'll need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised.
Speaker 1: To withdraw your question, please press star 1-1 again.
Speaker 1: Please be advised that today's conference is being recorded.
Speaker 1: Now I will turn the call over to Marci Graham, Senior Vice President of Investor Relations and Corporate Communications at Addy Bioscience. Ms. Graham, please go ahead.
Speaker 2: Thank you, Elizabeth. Good morning and welcome to the Addy Bioscience Conference call to review results of the fourth quarter and full year 2022 and to provide an update on our operation since the start of 2023. Joining me on the call today is Scott Giacobello, our CFO and interim president and CEO .
Speaker 2: who will provide an overview of financial and operational activity during the period, including an update on our continued commercial progress.
Speaker 2: Next will be our Chief Medical Officer, Dr. Loretta Eatrey, who will provide insights on our clinical development and plans for 2023. We will open the line for questions at the end of the call following the closing comments.
Speaker 2: Before we get started, a quick reminder that statements made on the call today will include forward-looking statements.
Speaker 2: Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the Risk Factors section of our annual and quarterly report filed with the Security and Exchange Commission.
Speaker 2: which can be found at www.scc.gov or on our website at www.aadiibio.com. In addition, any forward-looking statements made on this call represent our views only as of today, March 28, 2023.
Speaker 2: and should not be relied upon representing our views as of any subsequent date.
Speaker 2: We specifically disclaim any obligation to update or revise any forward-looking statement.
Speaker 2: With that, I will turn the call over to Scott for his opening statement. Scott?
Speaker 3: Thank you, Marcie, and hello, everyone.
Speaker 3: Thank you for joining us this morning to review our financial and operational results for the fourth quarter in full year 2022.
Speaker 3: As we said before, this past year was a transformational one for Addi.
Speaker 3: Though there are many, the top-line accomplishments of 2022 began early in the year with the successful commercial launch of our first product, Fiyaro, for the treatment of advanced malignant glaucoma.
Speaker 3: A rare form of sarcoma with no prior standard treatment.
Speaker 3: Upon launch, Biora was added to the NCCN clinical practice guidelines.
Speaker 3: as the only preferred treatment regimen for malignant pecoma, and we received a permanent J code for Fial
Speaker 3: facilitating payer coverage and reimbursement.
Speaker 3: We achieved sales of $15.2 million in 2022, outperforming estimates for the year in just 10 months on the market.
Speaker 3: This launch was closely followed by the initiation of our Phase II registration-directed trial, Decision 1.
Speaker 3: of studying patients with solid tumors that have TSC1 or TSC2 inactivating alterations in the mTOR pathway.
Speaker 3: We are excited about the potential for Fiyaro to provide benefits for patients beyond the common.
Speaker 3: We believe in our prospects and look forward to sharing preliminary data on a meaningful number of patients in the precision one trial in the second quarter of 2023.
Speaker 3: As we progressed on both the commercial and clinical fronts, we announced the completion of a pipe financing of $72.5 million.
Speaker 3: extending our runway into 2025, and supporting our ongoing operations and further expansion of our initiatives.
Speaker 3: This includes a collaboration with Marati Therapeutics, announced last fall, for a new combination clinical study in patients with KRAS G12C mutations.
Speaker 3: as part of our strategy to expand indications for Fiyaro.
Speaker 3: Beyond these advancements, we are pleased with the continued adoption of 5-RO for patients with picada.
Speaker 3: We achieved $5.2 million in sales for the fourth quarter, which represents growth of 23% over Q3.
Speaker 3: We continue to see increased uptake in the community setting, with roughly half of the business now coming from community clinics and hospitals.
Speaker 3: We are encouraged by the acceptance in the market of Fiyaro as a leading treatment option, and at the end of the year we had more than 120 unique ordering accounts.
Speaker 3: up 34% from the prior quarter with a reorder rate of more than 85%.
Speaker 3: Underscoring the positive clinical experience conveyed by healthcare providers who are increasingly viewing bi-R0 as the standard of care for their glaucoma patients.
Speaker 3: Lastly, we just announced the addition of Dr. Muhammad Hermans to our board of directors, who brings a rich history of success in clinical development and operational expertise to the role, currently serving as the chief medical officer of Avenzo Therapeutics, following his role as CMO at Turning Point Therapeutics, acquired by BMS last year.
Speaker 3: His impressive qualifications and broad expertise in clinical operations.
Speaker 3: and experiences at companies like Medivation and Peloton compliments the acumen of our existing board contributors. And we are truly looking forward to working with them as we advance the current Precision One trial and other new trials in the future. We are enthusiastic about what has become in 2023, heading into another year of solid execution, thanks in no small part to our team here at Addy.
Speaker 3: whose hard work is what made our achievements possible, and whose continued dedication is what will drive our progress in the future. Loretta is up next to further discuss our progress and ongoing clinical activity. Loretta?
Speaker 2: Thank you, Scott, and good morning everyone.
Speaker 2: On the clinical front, progress continues in our ongoing precision one tumor agnostic trial in patients with TFC1 or 2 inactivating alterations.
Speaker 2: The number of open sites has continued to increase along with access to patients, allowing us to achieve our goal of opening 120 sites by the end of 2022.
Speaker 2: Patient accrual remains on track, although we continue to deal with widespread staffing shortages as our sites work to recover from the impact of the COVID pandemic.
Speaker 2: The continuing commitment of our team and our maturing partnerships with the leading next generation sequencing companies have played a strategic role in affording access to patients.
Speaker 2: This has been an important factor in enabling us to routinely identify eligible patients, particularly in community-based practices.
Speaker 2: We appreciate our partnerships with US Oncology, TEMPUS, and Foundation Medicine as we work to identify patients who qualify for the trial.
Speaker 2: We believe that full patient enrollment into the study will be completed within 24 months from first patient treated in the spring of 2024.
Speaker 2: As presented at the recent Society for Gynecologic Oncology annual meeting just a few days ago in Tampa, Florida, a sub-analysis of the data from our pivotal AMPEC trial revealed excellent activities for napsorolumous in patients presenting with malignant uterine glaucoma.
Speaker 2: Our clinical team has been hard at work building relationships in the GYN oncology community, interacting with clinicians in the field to consider the options made available by napsoralimis in treating these patients.
Speaker 2: As we have previously mentioned, we continue to evaluate additional indications for NAB serolimus beyond glaucoma and TSC1 or 2 inactivating alterations.
Speaker 2: either as a single agent or in combination. We will be providing an update on new potential studies later in the year.
Speaker 2: We are also progressing well in our clinical collaboration with Marathi as we evaluate the combination of Adagrasib and NAPs serolamus in KRAS G12C mutant non-small cell lung cancer and other solid tumors. We expect that Marathi will dose the first patient in this trial during the second quarter of this year.
Speaker 2: As you may recall, we presented preclinical data on the combination of KRAS inhibitors and napsuralinib last fall at the AACR NCI-EORTC meeting that lays the foundation for our partnership on this combination strategy.
Speaker 2: to treat non-small cell lung cancer and other solid tumors with a KRAS G12C mutation.
Speaker 2: The team here at Adi is very busy and energized about continuing to explore the further potential benefits of napsorolimus in the treatment of patients with additional oncologic indications.
Speaker 2: I will now turn it back over to Scott for a financial update. Scott?
Speaker 3: Thanks, Loretta. We had a solid fourth quarter and ended a year of strong performance with approximately $172.6 million in cash, cash equivalents and short-term investments, including proceeds from the completion of our $72.5 million financing last fall.
Speaker 3: We begin 2023 well capitalized with the balance sheet that is expected to fund operations into 2025.
Speaker 3: Turning to our financial results.
Speaker 3: Fiyaro Net product sales amounted to $5.2 million for the fourth quarter and $15.2 million for 2022.
Speaker 3: As is typical at the end of the year, there was some inventory built at the specialty distributors in the quarter, and we expect this will normalize in the first quarter.
Speaker 3: Research and development expenses for the quarter increased to $9.4 million as compared to $7.2 million in the prior year quarter. For the year, R&D expense amounted to $32.7 million as compared to $19.7 million last year.
Speaker 3: This increase is primarily related to continued progress of the ongoing Precision-1 trial and the build-out of the R&D organization.
Speaker 3: Selling, general, and administrative expenses for the fourth quarter were $11.1 million compared to $9.7 million in the same period in 2021. For the year, SG&A expenses totaled $40.2 million compared to $18.5 million in the prior year.
Speaker 3: This increase is mainly due to the build-out of our commercial operations and company infrastructure and increased marketing expenses related to the commercial launch of Fiyaro.
Speaker 3: Net loss for the fourth quarter was $13.9 million compared to $16 million in the fourth quarter 2021.
Speaker 3: And that loss for the year was $60.5 million compared to $110.1 million in the prior year.
Speaker 3: The prior year included the non-cash impairment charge of $74.2 million related to the acquired contract intangible asset incurred in conjunction with the ARPO merger.
Speaker 3: For more information on our financial performance for 2022, a detailed discussion of the results reported on this call will be provided in our 10-K to be filed later today. As you heard today, 2022 was a transformational year for us.
Speaker 3: One that will set the foundation for the advancements that lie ahead in 2023. Our focus remains on the patients we serve and on providing therapies that improve the lives of those who suffer from mTOR driven diseases.
Speaker 3: We can now open the line for questions. Operator?
Speaker 1: As a reminder, if you'd like to ask a question at this time, please press star 1 1 on your telephone.
Speaker 1: Please stand by while we compile the Q&A roster. Our first question comes from the line of Roger Song with Jeffries.
Speaker 4: Great, congrats for the progress and thanks for taking the question. So a couple of questions from us. So the first one is the viral cells look pretty impressive in terms of the steady growth.
Speaker 5: Do you have any kind of anecdotal comments in terms of the patient characteristic you're getting on the treatment? Such as the line of therapy and the duration on treatment. And when do you expect you will be able to provide more?
Speaker 6: guidance in terms of the future sales. Thanks. Great, Roger. Thanks for the question. Take the first one, patient characteristics. I would say what we've seen and I think we've mentioned this before, is early on in the launch of Fiyoro and Pecoma, we were seeing patients, we were kind of meeting patients where they were in their treatment.
Speaker 7: plan in progress of therapy. And what we've seen after being on the market and physicians being more comfortable and knowing more about the drug is we've moved, we're moving closer to first line. And as we do that, we expect that that's going to have a positive impact on duration. Although I would say that we're still pretty early, just 10 months in.
Speaker 8: On the market, and so we still need a little more time to see how duration plays out. So I'd say we're probably still a ways away from guidance, but certainly very happy with the progress that we're seeing.
Speaker 9: Yep, thank you. And then, so, in terms of the precision, this preliminary result in Tool Q, I'm curious, what would you consider as the meaningful end, first of all, and also kind of a venue you will potentially report data?
Speaker 10: It will be in the medical meeting or company host to the event. I'll press. Thank you. Sure. So as far as a meaningful and what we've said is it will not be single digits. So the patients in the double digits.
Speaker 11: And as far as the venue, it will not be released at a scientific meeting, but rather a company press release or company event.
Speaker 12: Excellent, thank you. That's it for us and the Congress again. As a reminder, that is star 11 to ask a question. Our next question comes from the line of Ahu Demir.
Speaker 13: inpatient.
Speaker 14: Sure. So from a reimbursement perspective, which I think is your first question, Ah-Hoo, so what we're seeing from a lives covered perspective is that we're north of 85% of commercial lives covered at this point. So quality of access continues to be very strong.
Speaker 15: and we're seeing policies in place without restrictions. So we're very happy with that. And then could you remind me again of your second question? My question was how many patients we prescribe or how many physicians we prescribe, if they are all?
Speaker 16: Yeah, prescription. Well, remember, we don't get we don't really get much in the way of script data, right? Because Fiyaro is an IV therapy. And so we don't get patient level data. The best measure we have is really the number of ordering institutions which you can loosely correlate to patients and that's a launch to date number.
Speaker 17: But that would be the closest thing we have to actual patient data. Okay, thanks, Scott. And my second question is on the SGO presentation on the relevance of TSD1 and two alterations in endometrial cancers.
Speaker 18: Could you maybe elaborate more on the relevance, like the maybe percentage of patients who had the TFC-1, two alterations in endometrial cancers? Is there any specific subtypes that had TFC-1, two alterations occurring in those endometrial cancer patients?
Speaker 19: And maybe the part of the follow-up question is what have you shown in the expanded access program?
Speaker 20: The other part of the follow-up question is, what have you shown in the Expanded Access Program for the endometrial patients?
Speaker 21: I'm going to turn that first part of your question on the SGO data over to Loretta. Loretta, you want to handle that one? NIEC
Speaker 22: Sure. Can you hear me?
Speaker 23: Sure. Can you hear me? Yes.
Speaker 24: Hi, Ahu. So off the top of my head, I can't recall the incidence rates of TFC1-2 mutations. It is of the different tumor types, it's one of the higher. I would say...
Speaker 25: in the range of 3 to 4 percent of endometrial cancers expressed TSC1-Q mutations. This sub-analysis that we performed was a relatively small subset of the AMPEC study. But as you may be aware, there was literature to suggest that the AMPEC study was a relatively small subset of the AMPEC study.
Speaker 26: that piconus that occurred in patients with endometrial cancer had a relatively unfavorable response. Our data, in fact, showed a very favorable response of 43%.
Speaker 27: in this population. So I think we have shown rather definitively, or at least in the best collection of patients of this type, that the effect of Fiyero in picomas occurring in endometrial cancer is a...
Speaker 28: It's quite good. Did I answer your question? Yes, you did. And is there any subtype of endometrial cancer, low-grade, high-grade, that TSC1-2 alterations occur at a higher rate?
Speaker 29: Unfortunately, the number of patients that we had data for would not allow us to say anything definitive in that regard.
Speaker 30: Thank you very much. Maybe this is Neil Desai. Hi everyone. Maybe I can just jump in here. Like Loretta said, we don't have enough information at this point on the copy number high versus low and the relative TSE1 to TSE2.
Speaker 31: endometrial cancer patients on the EAP data that we have disclosed in ASCO 2021. And at least one of them, I mean, it was a small number, but at least one of them, after many lines of therapy, had responded and done very well and went off for a long period of time.
Speaker 32: that is star 11 to ask a question. We have a question from the line of Hongfei Zhu with Cowan.
Hi, thank you for taking my question. This is a four board speaker. My first question is regarding precision one. You mentioned you have some difficulty recruiting due to COVID of staffing shortage. Are we still expecting the final readout in 2024 or if you have any issues with the COVID-19 pandemic?
more precise timeline for that. Sure Loretta, you want to take that one?
Sure. Good morning. We, as I believe I may have mentioned in my prepared remarks.
Good morning. We, as I believe I may have mentioned in my prepared remarks.
We are very aware and our sites report that they are having continued problems relative to staffing related to the COVID pandemic. However, we have been able to continue accruing patients onto the trial as we planned and we do.
At this point, still believe that we will meet our stated goal of completing enrollment in the spring of 2024.
So I don't think that there's anything different. Thank you. My second question is regarding to the Merati collaboration. Could you just give a little more color of the data expectation?
Sure. You want to take that one? Yeah, sure. At this time, we haven't really spoken about the timing of data from that, but as Scott mentioned and Loretta mentioned, the timing of the initiation of the trial is in Q2.
at this point, and that's the information we have from Miradi. It is a phase one trial where, because it's a combination, that those need to be worked out. And so I think we can understand that that takes the usual amount of time for figuring out a combination.
I don't think we expect any results this year, but it's possible we might get something next year. We have to hear from Nivadi.
I don't think we expect any results this year, but it's possible we might get something next year, but again, that we have to hear from Niraadi. Thank you. Thank you for taking my question.
That concludes today's question and answer session. I'd like to turn the call back to Scott Giacobello for closing remarks.
Yes, I want to thank everyone for joining us today. As you can see, we're very excited about 2023. I'm looking forward to sharing more information later in the year. Thank you.
This concludes today's conference call. Thank you for participating. You may now disconnect.
I I have you.
At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session.
To ask a question during the session, you'll need to press star 1 1 on your telephone.
You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again.
Please be advised that today's conference is being recorded. Now I will turn the call over to Marcy Graham, Senior Vice President of Investor Relations and Corporate Communications at Addy Bioscience. Ms. Graham, please go ahead.
Thank you, Elizabeth. Good morning and welcome to the Addy BioScience Conference call to review results of the fourth quarter and full year 2022 and to provide an update on our operation since the start of 2023.
Joining me on the call today is Scott Giacobello, our CFO and interim president and CEO , who will provide an overview of financial and operational activity during the period, including an update on our continued commercial progress.
Next will be our Chief Medical Officer, Dr. Loretta Eatrey, who will provide insights on our clinical development and plans for 2023.
We will open the line for questions at the end of the call following closing comments. Before we get started, a quick reminder that statements made on the call today will include forward-looking statements.
Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section of our annual and quarterly report, filed with the Security and Exchange Commission, which can be found at www.scc.gov or on our website at www.aadi.io.com. In addition,
Any forward-looking statements made on this call represent our views only as of today, March 28, 2023, and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.
With that, I will turn the call over to Scott for his opening statement. Scott? Thank you, Marcy, and hello, everyone. Thank you for joining us this morning to review our financial and operational results for the fourth quarter in full year 2022. As we said before, this past year was a transformational one for Addie.
Though there are many, the top-line accomplishments of 2022 began early in the year with the successful commercial launch of our first product, Phi Orym, for the treatment of advanced malignant
a rare form of sarcoma with no prior standard treatment.
Upon launch, FYRO was added to the NCCN clinical practice guidelines as the only preferred treatment regimen from ligno-picoma, and we received a permanent J code for FYRO soon after, facilitating payer coverage and reimbursement.
We achieved sales of $15.2 million in 2022.
Outperforming estimates for the year in just 10 months on the market. This launch was closely followed by the initiation of our phase two registration directed trial, precision one, a study in patients with solid tumors that have TSC1 or TSC2 inactivating alterations in the mTOR pathway.
We are excited about the potential for Fiyaro to provide benefits for patients beyond the coma. We believe in our prospects and look forward to sharing preliminary data on a meaningful number of patients in the Precision One trial in the second quarter of 2023. As we progress on both the commercial and clinical front.
We announced the completion of a pipe financing of $72.5 million.
extending our runway into 2025, and supporting our ongoing operations and further expansion of our initiatives. This includes a collaboration with Marati Therapeutics, announced last fall, for a new combination clinical study in patients with KRAS G12C mutations, as part of our strategy to expand indications.
for PHYRO. Beyond these advancements, we are pleased with the continued adoption of PHYRO for patients with pecama.
We achieved $5.2 million in sales for the fourth quarter, which represents growth of 23% over Q3. We continue to see increased uptake in the community setting, with roughly half of the business now coming from community clinics and hospitals.
We are encouraged by the acceptance in the market of Fiyaro as a leading treatment option, and at the end of the year, we had more than 120 unique ordering accounts.
up 34% from the prior quarter with a reorder rate of more than 85%.
underscoring the positive clinical experience conveyed by healthcare providers who are increasingly viewing Phi R O as the standard of care for their PCOMA patient. Lastly, we just announced the addition of Dr. Muhammad Hermans to our board of directors.
who brings a rich history of success in clinical development and operational expertise to the role, currently serving as the Chief Medical Officer of Avenzo Therapeutics, following his role at CMO at Turning Point Therapeutics, acquired by BMS last year.
His impressive qualifications and broad expertise in clinical operations and experiences at companies like Medivation and Peloton complement the acumen of our existing board contributors, and we are truly looking forward to working with them as we advance the current Precision I trial and other new trials in the future.
We are enthusiastic about what has become in 2023, heading into another year of solid execution thanks in no small part to our team here at Addy. This hard work is what made our achievements possible and whose continued dedication is what will drive our progress in the future.
Loretta is up next to further discuss our progress and ongoing clinical activity. Loretta? Thank you, Scott, and good morning, everyone. On the clinical front, progress continues in our ongoing Precision-1 tumor agnostic trial in patients with TFC-1 or 2 inactivating alterations.
The number of open sites has continued to increase along with access to patients, allowing us to achieve our goal of opening 120 sites by the end of 2022. Patient accrual remains on track, although we continue to deal with widespread staffing shortages as our sites work to recover from the impact of the COVID pandemic.
The continuing commitment of our team and our maturing partnerships with the leading next generation sequencing companies have played a strategic role in affording access to patients. This has been an important factor in enabling us to routinely identify eligible patients, particularly in community-based practices.
We appreciate our partnerships with U.S. Oncology, TEMPIS, and Foundation Medicine as we work to identify patients who qualify for the trial. We believe that full patient enrollment into this study will be completed within 24 months from first patient treated in the spring of 2024. As presented at the recent Society for Gynecological...
in the GYN oncology community, interacting with clinicians in the field to consider the options made available by NAPS serolamists in treating these patients.
As we have previously mentioned, we continue to evaluate additional indications for nabsterolimus beyond glaucoma and TSC1 or 2 in activating alterations, either as a single agent or in combination. According to MAlaughterG studies, the lead cyclic-like reaction in any agent should
We will be providing an update on new potential studies later in the year. We are also progressing well in our clinical collaboration with Marathi as we evaluate the combination of adagressive and napsterolomous in KRAS G12C mutant non-small cell lung cancer and other solid tumors.
We expect that Merati will dose the first patient in this trial during the second quarter of this year. As you may recall, we presented preclinical data on the combination of K-RAS inhibitors and napsuralamus last fall at the AACR NCI-EORTC meeting that lays the foundation for our partnership on this combination strategy.
to treat non-small cell lung cancer and other solid tumors with a KRAS G12C mutation.
The team here at Adi is very busy and energized about continuing to explore the further potential benefits of napsuralnus in the treatment of patients with additional oncologic indications.
I will now turn it back over to Scott for a financial update. Scott? Thanks, Loretta. We had a solid fourth quarter and ended a year of strong performance with approximately $172.6 million in cash, cash equivalents, and short-term investments, including proceeds from the completion of our $72.5 million financing last fall.
We begin 2023 well capitalized with the balance sheet that is expected to fund operations into 2025. Turning to our financial results.
FiyaroNet product sales amounted to $5.2 million for the fourth quarter and $15.2 million for 2022. As is typical at the end of the year, there was some inventory billed at the special new distributors in the quarter, and we expect this will normalize in the first quarter.
Research and development expenses for the quarter increased to $9.4 million as compared to $7.2 million in the prior year quarter.
For the year, R&D expense amounted to $32.7 million as compared to $19.7 million last year. This increase is primarily related to continued progress of the ongoing Precision One trial and the build-out of the R&D organization. In general, the administrative expenses for the fourth quarter were $11.1 million.
in company infrastructure and increased marketing expenses related to the commercial launch of Fiyaro.
Net loss for the fourth quarter was $13.9 million compared to $16 million in the fourth quarter of 2021. Net loss for the year was $60.5 million compared to $110.1 million in the prior year. The prior year included the non-cash impairment charge of $74.2 million related to the acquired contract intangible asset.
incurred in conjunction with the airfield merger. For more information on our financial performance for 2022, a detailed discussion of the results reported on this call will be provided in our 10k to be filed later today.
As you heard today, 2022 was a transformational year for us, one that will set the foundation for the advancements that lie ahead in 2023. Our focus remains on the patients we serve and on providing therapies that improve the lives of those who suffer from end-to-end diseases.
We can now open the line for questions. Operator? As a reminder, if you'd like to ask a question at this time, please press star 1 1 on your telephone.
Please stand by while we compile the Q&A roster. Our first question comes from the line of Roger Song with Jefferies. Great. Congrats for the progress and thanks for taking the question. So a couple of questions from us.
So the first one is the viral cells looks pretty impressive in terms of the steady growth. Do you have any kind of anecdotal comments in terms of the patient characteristic you're getting on the treatment, such as the line of therapy and the duration on treatment? And when do you expect you will?
be able to provide more guidance in terms of the future sales. Thanks. Great, Roger. Thanks for the question. Take the first one for patient characteristics. I would say what we've seen, and I think we've mentioned this before, is early on in the launch of Biora and Pecoma.
We were seeing patients, we were kind of meeting patients where they were in their treatment plan and progressive therapy. And what we've seen after being on the market and physicians being more comfortable and knowing more about the drug is we've moved, we're moving closer to first line. And as we do that, we expect that that's going to have a positive impact on duration. Although I would say that we're still pretty early, just 10 months in. By the end of 2020.
On the market, and so, you know, we still need a little more time to see how duration plays out. So, I'd say we're probably still a ways away from guidance, but certainly very happy with the progress that we're seeing. Yep, thank you. And then, so, in terms of the precision, this preliminary result in tool queue.
Curious, what would you consider as the meaningful end, first of all, and also kind of what kind of a venue you will potentially report the data. It will be in the medical meeting or company hosted event or press release. Thank you.
Sure. So, as far as a meaningful end, what we've said is it will not be single digits. So it will be patients in the double digits. And as far as the venue, it will not be released at a scientific meeting, but rather a company press release or company event. Excellent.
Thank you. That's it for us and the Congress again. As a reminder, that is star 1-1 to ask a question. Our next question comes from the line of Ahu Demir with Lattenberg.
Good morning. Thank you so much for taking my question. I have two questions. First one is on the revenues. If you could provide more color on the percentage of patients' lives covered and also the prescription rate of VRO in patients.
Sure. So from a reimbursement perspective, which I think is your first question, Ah-Hoo, so what we're seeing from a lives covered perspective is that we're north of 85% of commercial lives covered at this point. So quality of access continues to be very strong and we're seeing policies in place without restrictions. So we're very happy with that.
And then could you remind me again of your second question? My question was how many patients we prescribe or how many physicians we prescribe for ARL?
Well, remember, we don't get we don't really get much in the way of script data, right? Because Fiyaro is an IV therapy, and so we don't get patient level data. We get that measure.
we have is really the number of ordering institutions, which you can loosely correlate to patients, and that's a launch to date number. But that would be the closest thing we have to actual patient data.
Okay, thanks, Scott. And my second question is on the SGO presentation on the relevance of TFC-1 and 2 alterations in endometrial cancers. Could you maybe elaborate more on the relevance, like the maybe percentage of patients who had the TFC-1, 2 alterations in endometrial cancers?
Is there any specific subtypes that TSC1, 2 alterations are curing those endometrial cancer patients? And maybe part of the follow-up question is, what have you shown in the Expanded Access Program? Dr.
for the, again, endometrial patients. Okay, so I'm going to turn that first part of your question on the SGO data over to Loretta. Loretta, you want to handle that one? Sure. Can you hear me? Yes.
Hi, Ahu. So off the top of my head, I can't recall the incidence rates of TFC1-2 mutations. It is, of the different tumor types, it's one of the higher, I would say, in the range of 3 to 4% of endometrial cancers.
with endometrial cancer had a relatively unfavorable response. Our data in fact showed a very favorable response of 43% in this population. So I think we have shown rather definitively.
or at least in the best collection of patients of this type, that the effect of Cliaro in picomas occurring in endometrial cancer is quite good.
in the best collection of patients of this type that the effect of Cliaro in picomas occurring in endometrial cancer is quite good. Did I answer your question?
Yes, you did. And is there any subtype of endometrial cancer, low-grade, high-grade, that TSC1-2 alterations occur at a higher rate? Unfortunately, the number of patients that we had data for would not allow us to say anything definitive in that regard.
Thank you very much. This is Neil Desai. Hi everyone. Maybe I can just jump in here. Like Loretta said, we don't have enough information at this point on the copy number high versus low and the relative TSE1-2.
but that is an area we continue to look. I think you had another question on the EAP and as relates to endometrial. And if you would recall, we did have endometrial cancer patients, and this was not the coma, but endometrial cancer patients on the EAP data that we had disclosed in ASCO 2021. And at least one of them, I mean, it was a small number.
But at least one of them, after many lines of therapy, had responded and done very well and went off for a long period of time when we did the cutoff for the ASCO data, which was, I believe, over six months. Very helpful. Thanks for taking my question.
As a reminder, that is star 11 to ask a question.
We have a question from the line of Hongfei Xu with Cowen. Hi, thank you for taking my question. This is Hongfei Xu, a four-board speaker. My first question is regarding Precision I. You mentioned you have some difficulty recruiting due to COVID-19.
Good morning. We, as I believe I may have mentioned in my prepared remarks,
As I believe I may have mentioned in my prepared remarks.
We are very aware and our sites report that they are having continued problems relative to staffing related to the COVID pandemic. However, we have been able to continue accruing patients onto the trial as we planned. We do at this point still believe that we will meet our state's needs.
color of like the data expectation.
Sure. You want to take that one?
Yeah, sure. At this time, we haven't really spoken about the timing of data from that, but as Scott mentioned and Loretta mentioned, the timing of the initiation of the trial is in Q2 at this point, and that's the information we have from Miradi.
It is a phase one trial where, because it's a combination, that those need to be worked out. And so, I think we can understand that that takes the usual amount of time for figuring out a combination.
So, I don't think we expect any results this year, but it's possible we might get something next year, but again, that we have to hear from NARADI. Thank you. Thank you for taking my question. That concludes today's question and answer session. I'd like to turn the call back to Scott Giacobello for closing remarks.
Yes, I want to thank everyone for joining us today. As you can see, we're very excited about 2023 and looking forward to sharing more information later in the year. Thank you all. This concludes today's conference call. Thank you for participating. You may now disconnect. Thanks Everybody.